Richard Kelly, MD
Internal Medicine · Phoenix, AZNPI 1528068178
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,723 of the $3,621 with a category attached, or 75.2%. 23 manufacturers reported payments, led by AstraZeneca at 24.1% of the total. Reporting peaked in 2021 at $1,365 and has fallen 95.6% since, to $60 in 2025. Among internal medicine clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 136 payments — averaging $26.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$873
- AbbVie$399
- Sanofi-aventis U.S. LLC$390
- Astellas Pharma US Inc$250
- GSK$237
- Abbott$197
- plus $1K from 17 others
Across 24 payments — averaging $4828.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$59K
- GSK$50K
- Pfizer$7K
What the payments were for
- Consulting fees$76821%
- Food & beverage$2,72375%
- Education$1314%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $873 |
| AbbVie(2 entities) | 27 | $399 |
| Sanofi-aventis U.S. LLC | 8 | $390 |
| Astellas Pharma US Inc | 11 | $250 |
| GSK | 9 | $237 |
| Abbott | 10 | $197 |
| Pfizer | 17 | $170 |
| Amgen | 9 | $164 |
| Lilly USA, LLC | 9 | $158 |
| Novo Nordisk | 3 | $149 |
| Shockwave Medical, Inc | 1 | $129 |
| Optinose US, Inc. | 1 | $123 |
| Dexcom, Inc. | 6 | $84 |
| Boehringer Ingelheim | 4 | $56 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Merck | 2 | $29 |
| Johnson & Johnson | 1 | $24 |
| Lifescan, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Almatica Pharma LLC | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,621 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 38 | $856 |
| Atorvastatin Calcium | 64 | $828 |
| Levothyroxine Sodium | 59 | $625 |
| Fluticasone Propionate | 26 | $596 |
| Gabapentin | 22 | $519 |
| Metformin Hcl | 45 | $497 |
| Lisinopril | 54 | $412 |
| Famotidine | 12 | $411 |
| Hydroxyzine Hcl | 15 | $386 |
| Pioglitazone Hcl | 12 | $347 |
| Amlodipine Besylate | 56 | $317 |
| Losartan Potassium | 28 | $295 |
| Fluconazole | 17 | $293 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 25 | $284 |
| Rosuvastatin Calcium | 15 | $248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $62559 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Phoenix
- Frank LovecchioPhoenix$911K
- Nasser HajaigPhoenix$687K
- Kelly KrohnPhoenix$262K
- Paul StanderPhoenix$222K
- Howard GrossmanPhoenix$131K
- Nafis Shamsid-DeenPhoenix$115K
- Shishir MurarkaPhoenix$79K
- Mark WongPhoenix$71K
- Geoffrey OrmePhoenix$27K
- Roberto RuizPhoenix$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.